

**Study of Different Methods and Concentrations of
Mitomycin C Application in Subscleral Trabeculectomy
in Rabbits**

Thesis

Submitted for partial fulfillment of the M.D. in
Ophthalmology

By

Karim Magdi Naguib
M.B.B.Ch., MSc. Ophthalmology

Supervised by

Prof. Dr. Mohamed Adel Abdel Shafik
Professor of Ophthalmology
Faculty of Medicine, Ain Shams University

Prof. Dr. Sanaa Abdel-Maged Sammour
Professor of Pathology
Faculty of Medicine, Ain Shams University

Prof. Dr. Ali Hassan Saad
Professor of Ophthalmology
Faculty of Medicine, Ain Shams University

Prof. Dr. Hany Mohamed Hassan El Ibiary
Professor of Ophthalmology
Faculty of Medicine, Ain Shams University

Faculty of Medicine
Ain Shams University
Cairo
2009

دراسة الطرق و التركيزات المختلفة لاعطاء عقار ميتومايسين ج فى عمليات الراشحة المحمية فى الارانب

رسالة
توطئة للحصول على درجة الدكتوراة
فى طب و جراحة العيون

مقدمة من
الطبيب /كريم مجدى نجيب
مدرس مساعد طب و جراحة العيون
كلية الطب - جامعة عين شمس

تحت اشراف

الاستاذ الدكتور/ محمد عادل عبدالشفيق
استاذ طب و جراحة العيون
كلية الطب جامعة عين شمس

الاستاذ الدكتور/ سناء عبدالماجد سمور
استاذ الباثولوجى
كلية الطب جامعة عين شمس

الاستاذ الدكتور/على حسن سعد
استاذ طب و جراحة العيون
كلية الطب جامعة عين شمس

الاستاذ الدكتور/ هانى محمد حسن الالبيارى
استاذ طب و جراحة العيون
كلية الطب جامعة عين شمس

كلية الطب
جامعة عين شمس
القاهرة
2009

Table of figures

	figure	page
1	Filtering bleb	7
2	Light microscopy of filtering bleb and failed bleb	7
3	Targets for molecular therapy	15
4	The cell cycle and relationship of different anti-metabolite agents action to the cycle	35
5	Mitomycin C molecule	36
6	Hypotonus maculopathy	40
7	choroidal detachment	40
8	Large overhanging bleb	41
9	bleb leak	42
10	bleb infection	42
11	reconstituted MMC 0.4 mg/ml	43
12	intra operative application of MMC	45
13	Simple changes minimize the occurrence of complications after trabeculectomy.	46
14	Difference between large and small application area of MMC	47

15	Post operative sponge application of MMC.	49
16	topical anesthesia application	52
17	application of fluoerscin in the conjunctival sac	53
18	Checking the intra ocular pressure	53
19	reconstituted MMC.	54
20	intra muscular injection of ketamine	56
21	Steps of surgery	58
22	postoperative application of MMC	60
23	post operative appearance group (1)	65
24	post operative appearance group (2)	65
25	post operative appearance group (3)	66
26	post operative appearance group (4)	66
30	Histological aspect of the surgical area in group (1) H&E	79
31	Histological aspect of the surgical area in group (1) PAS	80
32	Histological aspect of the surgical area in group (2) H&E	81

33	Histological aspect of the surgical area in group (2) PAS	82
34	Histological aspect of the surgical area in group (3) H&E	83
35	Histological aspect of the surgical area in group (3) PAS	84
36	Histological aspect of the surgical area in group (4) H&E	85
37	Histological aspect of the surgical area in group (4) PAS	86
38	TEM of collagen fibers in group (1)	87
39	TEM of collagen fibers in group (2)	87
40	TEM of collagen fibers in group (3)	88
41	TEM of collagen fibers in group (4)	88
42	TEM of ciliary body epithelium in group (1)	89
43	TEM of ciliary body epithelium in group (2)	90
44	TEM of ciliary body epithelium in group (3)	90
45	TEM of ciliary body epithelium in group (4)	91
46	Eye B9 showing bleb infection.	92

LIST OF TABLES

	Table	Page
1	Mean preoperative IOP in the different groups	63
2	Mean IOP of group (1)	67
3	Mean IOP of group (2)	68
4	Mean IOP of group (3)	69
5	Mean IOP of group (4)	70
6	The daily change of IOP	71
7	Reduction in the mean IOP after application of MMC	73
8	Time and number of bleb failure	75
9	Median duration of bleb survival	76
10	comparison between the mean duration of bleb survival in the study groups	77

LIST OF GRAPHS

	Graph	Page
1	Mean preoperative IOP in the different groups	64
2	Mean IOP of group (1)	67
3	Mean IOP of group (2)	68
4	Mean IOP of group (3)	69
5	Mean IOP of group (4)	70
6	Comparison between the control group and the study groups as regards the mean IOP.	72
7	Comparison between the preoperative and post operative mean iop among the control and the study groups.	74
8	Number of surviving blebs over the follow up period	75
9	Comparison between the study groups as regards the median duration of glaucoma bleb survival.	76

LIST OF ABBREVIATIONS

- o 5 – FU : 5 fluorouracil
- o 5- CU : 5- Chlorouracil
- o 5- FC : 5-Fluoro cytosine
- o AC : Anterior Chamber
- o AGIS : Advanced glaucoma intervention study
- o ANOVA : Analysis of variance
- o BAK : Benzalkonium chloride
- o BSS : Balanced salt solution
- o CAT : Cambridge antibody technology
- o DNA : Deoxyribonucleic acid
- o ECM : Extra cellular matrix
- o H&E : Hematoxylin and Eosin
- o HLA : Human lymphocyte antigen
- o HTF : Human tenon fibroblasts
- o IFN : Interferon
- o IOP : Intraocular pressure
- o M-6-P : mannose-6-phosphate
- o MMC : Mitomycin C
- o MMP : Matrix MetalloProteinase
- o mRNA : messenger ribonucleic acid
- o NIH : National Institutes of Health
- o NTG : Normal Tension Glaucoma
- o OGN :Oligonucleotide.
- o P : Probability.
- o PAS : Periodic Acid Schiff
- o PBS : Phosphate-buffered saline
- o PDT : PhotoDynamic Therapy
- o POAG : Primary Open Angle glaucoma
- o POE : Poly Ortho Esters
- o SD : Standard deviation
- o TGF- β : Transforming growth factor beta
- o tPA2 : Tissue plasminogen activator
- o tTgase : Tissue transglutaminase

Acknowledgment

I would like to express my sincere gratitude and heartfelt thanks to Professor Mohamad Adel Abdel Shafik, Professor Sana Samour, Professor Ali Saad and Professor Hani El Ibiary for their valuable guidance, expert assistance and fruitful criticism.

Index

<i>Introduction.....</i>	<i>1</i>
<i>Modulation of wound healing.....</i>	<i>5</i>
<i>Antimetabolites</i>	<i>33</i>
<i>Material and methods.....</i>	<i>51</i>
<i>Results</i>	<i>63</i>
<i>Discussion.....</i>	<i>93</i>
<i>Conclusion.....</i>	<i>103</i>
<i>References.....</i>	<i>105</i>
<i>Arabic summary</i>	

INTRODUCTION

Glaucoma is a leading cause of blindness worldwide and is the second most frequent cause of legal blindness in industrialized countries. In glaucoma the optic nerve is progressively damaged causing defects in the visual field, usually asymptomatic until the central vision is affected.

The goal of glaucoma management is to preserve the patient's quality of life. The only treatment option proved to prevent the loss of vision is to lower the intraocular pressure to a level deemed safe for the eye. Classically speaking, the recommended steps for lowering the intraocular pressure in primary open angle glaucoma (POAG) are topical medications first, followed by laser trabeculoplasty and, lastly, incisional surgery (**Traverso et al., 2005**).

Surgical failures of trabeculectomies are in most cases caused by a wound healing response at the level of the episclera and the deep fibrovascular layers of Tenon's capsule that evoke a permanent increase of outflow resistance or even complete occlusion. While this obstruction is less common in patients with uncomplicated primary open angle glaucoma (POAG), it is a frequent complication in patients undergoing

repeated procedures or with other forms of glaucoma. The trabeculectomy success rates for POAG range from 24% to 75 % (**Mietz et al., 1998**).

Recent data from the NIH advanced glaucoma intervention study (AGIS) have shown that individuals with the lowest intraocular pressures (average 12.3 mm Hg) had virtually no overall glaucomatous progression over nearly a decade. The healing response after surgery is the main long term determinant of long term post operative intraocular pressure. Therefore, if we are able to control the healing response in all patients after glaucoma surgery, it offers us the tantalizing prospect of minimal or no disease progression in the vast majority of our glaucoma patients, even those with advanced disease (**Khaw et al., 2002**).

However, current studies do reveal that none of the current operations for glaucoma are totally ideal yet, and further research, particularly on surgical methods and wound healing control, is needed so that optimal long term pressure control can be achieved for all our patients with a minimum of complications (**Khaw et al., 2003**).

Rabbit models of glaucoma filtration surgery, although commonly used experimentally, represent a very aggressive scarring response compared with that in humans. Therefore,

virtually every agent shown to reduce scar tissue formation in the rabbit is effective in humans (**Cordeiro et al., 1999(a)**).

Because of the aggressive wound-healing response in rabbits with surgical failure mostly occurring within 1 week, this animal model is believed to be equivalent to high-risk eyes in humans. The use of antifibrotic drugs, such as 5-fluouracil and mitomycin C, prolongs bleb survival. However, the effect is not permanent and, depending on drug concentration, it will subside within 2 weeks (**Grisanti et al., 2005**).

Mitomycin-C has a profound inhibitory effect on the scarring response after glaucoma filtration surgery. Estimates suggest that intraoperative mitomycin C is used in at least 50% of primary trabeculectomies in the United States and Japan. The benefits derived from the antiscarring activity have, however, been tempered by a possible increase in postoperative complications, including chronic hypotony, bleb leak, and endophthalmitis (**Crowston et al., 2002**).

The advantages of single dose intra operative administration of MMC include convenience, ease of administration and proven efficacy. However it is difficult to titrate dosage to each patient (**El-Harazi et al., 1999**).

El-Harazi et al., in 1999 reported the effectiveness of low dose post operative application of MMC in rabbits.

An early description of MMC topical use appeared in the Japanese literature. **Kunimoto and Mori** in 1963 used a concentration of 0.04% three times daily for 1 to 2 weeks after pterygium surgery, with no recurrences. A number of subsequent articles from both Asia and North America have confirmed their good results, with pterygium recurrence rates of 2% to 16% (**Waller and Adamis, 2002**).

Modulation of wound healing

Wound healing:

The conjunctival wound healing response is a major determinant of outcome following glaucoma filtration and squint surgery (**Addicks et al., 1983**).

Wound healing is a complex and dynamic process of restoring cellular structures and tissue layers. The human adult wound healing process can be divided into 3 distinct phases: the inflammatory phase, the proliferative phase, and the remodeling phase (**Mercandetti, 2005**).

The inflammatory phase is characterized by the influx of neutrophils and monocytes to the wound area followed by lymphocytes and macrophages, and the release of a variety of growth factors and other molecules. Re-epithelialisation and an increase in fibroblast activity and number occur in the proliferative phase, as also does angiogenesis and the laying down of granulation tissue. The remodeling phase consists of fibroblasts mediating the processes of wound contraction, extracellular matrix deposition, degradation and modification